One hundred patients from the outpatient department and the endoscopy unit at AUBMC will be enrolled in this open-label single arm trial. Patients with positive CLO tests or urea breath tests, or histological documentation of H. pylori infection, will be enrolled in the study. The patients will be followed up by phone calls on day 10 for side effects and for pill count. Patients will be assessed for the presence of these side effects at the end of the treatment (Day 10). A urea breath test will be done for all patients after ≥ 4 weeks of therapy completion and a minimum of 2 weeks of PPI therapy to evaluate eradication rates